Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib with or without Panitumumab in Advanced Solid Tumors (ComboMATCH)
NCT05638295Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2024
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sotorasib and panitumumab in solid tumor (3 cohorts), sponsored by National Cancer Institute. Primary endpoints: Progression-Free Survival up to 3 years, Best objective response up to 3 years and 1 more. Started Aug 2024; status: active, not recruiting.
02
Drugs
sotorasibpanitumumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05638295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638295.